Related Experiment Video
Updated: Sep 20, 2025
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.8K
Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management-A
Hrvoje Kaučić1,2, Domagoj Kosmina1, Dragan Schwarz1,3,4
1Specijalna bolnica Radiochirurgia Zagreb, Ulica Dr. Franje Tuđmana 4, 10431 Sveta Nedelja, Croatia.
Cancers
|June 10, 2022
Summary
Stereotactic ablative radiotherapy (SABR) using Calypso® tracking for locally advanced pancreatic cancer (LAPC) shows promising efficacy and safety. This approach offers a viable local treatment option with acceptable toxicity, potentially improving outcomes when combined with systemic therapy.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Stereotactic Ablative Radiotherapy (SABR) is an advanced radiation technique.
- Locally Advanced Pancreatic Cancer (LAPC) presents treatment challenges.
- Calypso® Extracranial Tracking offers fiducial-based, intrafractional motion management.
Purpose of the Study:
- Evaluate SABR efficacy and safety for LAPC using Calypso® tracking.
- Present the Calypso® motion management technique for SABR in LAPC.
- Report clinical outcomes of this treatment approach.
Main Methods:
- Fifty-four LAPC patients treated with SABR (1, 3, or 5 fractions).
- Median biologically effective dose (BED10) of 112.5 Gy administered.
- Calypso® Extracranial Tracking used for intrafractional motion management.
- Systemic treatment received by 38 patients.
- Overall Survival (OS), Freedom From Local Progression (FFLP), Progression-Free Survival (PFS), and toxicity assessed.
Main Results:
- Median follow-up of 20 months.
- Median Overall Survival (OS) of 24 months.
- One-year FFLP and OS rates of 100% and 90.7%, respectively.
- Median Progression-Free Survival (PFS) of 18 months; one-year PFS of 72.2%.
- No acute or late toxicity exceeding Grade 2 reported.
Conclusions:
- SABR with Calypso® tracking is effective and safe for LAPC.
- This modality is a promising local therapeutic option with acceptable toxicity.
- Combination with systemic treatment and dose escalation may improve outcomes.
